life scienc tool diagnost
price month
 close
solid oper beat fine-tun ep
line item
ep top consensu ep beat
estim stronger revenu profit note adjust
guidanc vs consensu reflect latest
ep upsid off-set impact equiti offer dilut
relat ge biopharma deal similarli lower
ep aforement factor rais tp
ebitda encourag core strength
across busi line
revenu profit exceed plan organ revenu well
ahead strength life scienc vs estimate
diagnost vs despit difficult comp lighter flu
season dental improv nice vs trend
anem albeit easi comp rose vs
gross margin fell bp bp plan howev lower administr
expens bp help drive ebitda margin expans bp
bp plan million help fund million
dividend million debt paydown
share grind higher posit amid hc market disloc
share sinc announc acquisit ge
biopharma vs view share move higher
latest upsid across relev line item deemphas
recent hc market disloc view life sciences/tool sector
inher less directli tie recent concern healthcar reform
thu view recent pressur share like sympathi
broader hc unwarr concept medicar could
also repres opportun topic call ge/dent spin updat end-
market demand trend particularli biopharma/china upside/downsid
guidanc risk util macro condit miscu
valuat metric
number share
suiss seek busi compani cover research report result investor awar
firm may conflict interest could affect object report investor consid report
singl factor make invest decis
lead manufactur system instrument
consum broad array purpos custom
diagnost dental environment health/appli scienc
price apr rate outperform target price analyst erin wright
profit tax
chang work capit
flow oper
free cash-flow firm
flow invest
chang net cash/debt
total liabil equiti
share wtd average
price book
roe stated-return
 close
acceler key end market global signific rebound
dental trend better expect implement db
acquir compani market share gain materi margin
grey sky scenario base signific weak
key end market prolong weak dental demand trend
deceler core growth acquisit integr headwind
compani mention price
